Sam Altman Unveils $1 Billion AI Plan Targeting Disease Cures

Sam Altman announced a $1 billion investment plan through the OpenAI Foundation, focusing on disease research, AI resilience, and economic impact. The announcement follows OpenAI’s recapitalization, which enabled the Foundation to access major funding for large-scale programs.

Sam Altman AI Plan Targets Life Sciences and Disease Research

Sam Altman confirmed that a major portion of the funding will focus on life sciences and curing diseases. The Foundation identified three areas as initial priorities. These include Alzheimer’s research, expanding public health data, and accelerating progress in high-mortality diseases, alongside developments such as OpenAI introducing a smart contract benchmark for AI agents as AI and crypto converge.

AI will help discover new science, such as cures for diseases, which is perhaps the most important way to increase quality of life long-term.
AI will also present new threats to society that we have to address. No company can sufficiently mitigate these on their own; we will…
— Sam Altman (@sama) March 24, 2026

Researchers will use AI systems to outline disease stages and identify biomarkers for clinical applications. The plan also supports efforts to recycle existing FDA-approved treatments. According to the Foundation, AI can help shorten timelines between laboratory discovery and patient use.

The initiative also includes building open and high-quality datasets. These datasets will support researchers working across multiple disease categories. The OpenAI Foundation stated that broader data access remains critical for advancing AI-driven medical research.

OpenAI Foundation Expands Focus on AI Resilience and Safety

The OPENAI Foundation also described an ordered approach to AI resilience. Sam Altman stated that advanced AI systems pose risks that need coordinated responses. The OpenAI Foundation will oversee these risks through targeted research and partnerships.

Initial efforts will focus on children’s and youth’s safety. The program will support studies of the effects of AI on development and behavior. It will also discuss protections for safer interactions with AI systems.

The initiative will also invest in the safety of AI models. This includes independent evaluations, new industry standards and early detection systems for potential failures.

Leadership Changes and Additional Investment Strategy

Sam Altman also announced leadership updates to support OpenAI’s expansion. Jacob Trefethen will oversee life sciences programs. Anna Makanju will lead AI for civil society and philanthropy. Robert Kaiden will serve as Chief Financial Officer, while Jeff Arnold will direct operations.

The Foundation will also continue funding community-based organizations. These groups will help individuals understand and adapt to AI-driven changes. The initiative builds on the earlier People-First AI Fund, with further grants expected.

This follows a previous announcement linking BitMine and Tom Lee to OpenAI, though the exposure comes indirectly through Orbs rather than a direct investment.

In addition, Altman’s broader investment activity includes backing Retro Biosciences, which is raising $1 billion to develop therapies for age-related diseases. The company’s research includes Alzheimer’s treatments and cell-based therapies, while its approach uses AI to design proteins that reprogram cells into stem cells.

Source: https://coingape.com/openai-news-sam-altman-unveils-1-billion-ai-plan-targeting-disease-cures/